Trends in Pharmacological Sciences
ReviewChemokines, chemokine receptors and small-molecule antagonists: recent developments
Section snippets
Chemokines and receptors
Initially, in the late 1980s, chemokines and their receptors were described as key players in host defense, based on their potent activity in leukocyte migration and recruitment. Chemokines are classified (CC, CXC, CX3C and XC) based on the number and sequential relationship of the first two of four conserved cysteine residues. Initially, it was envisaged that the CXC chemokine receptors would be important targets for acute inflammation and CC chemokine receptors would be important targets for
Assigning potential targets of disease states
Because of the inherent complexity of the chemokine–chemokine-receptor axis, determined by expression patterns, post-translational modifications and the overlapping ligand–receptor specificities, the primary indication of therapeutic potential for this family comes from examining results from knockout animals in models of human disease states. However, because chemokines and chemokine receptors have roles in hematopoiesis and development, responses in knockout animals might not reflect the
General features of chemokine receptor antagonists
Chemokine receptor antagonists appear to share common features. First, the majority of these molecules contain a basic region, exemplified by the presence of piperidine, piperazine, spiropiperidine, pyrrolidine, guanidine, quaternary nitrogen or bicyclam groups. Second, many of them appear to have a preference for halogen-modified aromatic rings. The molecular basis for potent antagonism of CCR2 by the Roche spiropiperidine-derived compounds appears to involve an ionic interaction of the basic
Challenges facing inhibitor development programs
Because chemokine receptors are closely related to other Class A GPCR members it is not surprising to find examples of small-molecule antagonists that cross-react with other GPCRs. This appears to be particularly true for several chemokine receptor antagonists, which cross-react with biogenic amine receptors. For example, Schering-Plough's piperazine-based CCR5 inhibitors cross-react with muscarinic acetylcholine receptors [42], whereas Roche's CCR2 spiropiperidine inhibitor series cross-reacts
Concluding remarks
In the late 1980s scientists isolated the signaling molecules, termed chemokines, that allowed leukocytes to communicate with one another and seek out and destroy invading pathogens. However, the immune response is a double-edged sword and can, under some circumstances, be activated inappropriately and targeted towards normal, healthy tissue, which leads to autoimmunity and disease. In the space of 6 years, numerous, non-peptide chemokine receptor antagonists have been identified and some have
Acknowledgements
We would like to acknowledge researchers whose work is not specifically referenced owing to space limitations.
References (59)
Modelling G-protein-coupled receptors for drug design
Biochim. Biophys. Acta
(1999)The CC chemokine eotaxin (CCL11) is a partial agonist of the chemokine receptor CCR2b
J. Biol. Chem.
(2001)CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist
Blood
(1999)Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist
J. Biol. Chem.
(1996)Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors
J. Biol. Chem.
(1999)Differential activation of CC chemokine receptors by AOP-RANTES
J. Biol. Chem.
(2000)Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family
J. Biol. Chem.
(2001)CD26, let it cut or cut it down
Immunol. Today
(1999)TACE (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1)
J. Biol. Chem.
(2001)Fractalkine shares signal sequence with TARC: gene structures and expression profiles of two chemokine genes
Genomics
(2001)
Chemokine receptors
Cytokine Growth Factor Rev.
Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. Binding to a common chemokine receptor motif within the helical bundle
J. Biol. Chem.
Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor
J. Biol. Chem.
A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry
J. Biol. Chem.
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5
J. Biol. Chem.
The second extracellular loop of CCR5 is the major determinant of ligand specificity
J. Biol. Chem.
Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor
Eur. J. Pharmacol.
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element
Bioorg. Med. Chem. Lett.
CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound
Bioorg. Med. Chem. Lett.
Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor
J. Biol. Chem.
Molecular basis for the species specificity of the substance P antagonist CP-96,345
J. Biol. Chem.
Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function
J. Biol. Chem.
Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1(: implications for development of selective CXCR4 antagonists
Immunol. Lett.
Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope
Biochem. Biophys. Res. Commun.
Comodulation of CXCR4 and CD26 in human lymphocytes
J. Biol. Chem.
G-protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin
Curr. Opin. Drug Discov. Dev.
Structural mimicry in G-protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors
Mol. Pharmacol.
Crystal structure of rhodopsin: a G-protein-coupled receptor
Science
Subcommittee on Chemokine Nomenclature Chemokine/chemokine receptor nomenclature
J. Leukocyte. Biol.
Cited by (195)
Membrane-induced organization and dynamics of the N-terminal domain of chemokine receptor CXCR1: insights from atomistic simulations
2018, Chemistry and Physics of LipidsDiscovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities
2016, European Journal of Medicinal ChemistryCitation Excerpt :Long-term experiments were needed to make sure whether inhibiting this receptor has unfavorable influence on human. Moreover, CXCR4 and other GPCRs were characterized by high homology, thus, in the discovery and development of CXCR4 antagonist, there was so much to learn from other chemokine receptor counterparts [16]. Up to now, several kinds of CXCR4 antagonists have been reported including peptide analogues such as T22, T134, T140 FC131 and ALX40-4C etc, and non-peptide small molecular antagonists such as AMD3100, AMD070, IT1t and KRH-3395 (Fig. 2) [7,17–21].
Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists
2015, Organic and Biomolecular ChemistryCircRNA LOC729852 promotes bladder cancer progression by regulating macrophage polarization and recruitment via the miR-769-5p/IL-10 axis
2024, Journal of Cellular and Molecular Medicine